NO20014935L - Middel for forbedring av ketose - Google Patents

Middel for forbedring av ketose

Info

Publication number
NO20014935L
NO20014935L NO20014935A NO20014935A NO20014935L NO 20014935 L NO20014935 L NO 20014935L NO 20014935 A NO20014935 A NO 20014935A NO 20014935 A NO20014935 A NO 20014935A NO 20014935 L NO20014935 L NO 20014935L
Authority
NO
Norway
Prior art keywords
improving ketosis
ketosis
improving
agent
low toxicity
Prior art date
Application number
NO20014935A
Other languages
English (en)
Norwegian (no)
Other versions
NO20014935D0 (no
Inventor
Hiroyuki Odaka
Masami Suzuki
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NO20014935D0 publication Critical patent/NO20014935D0/no
Publication of NO20014935L publication Critical patent/NO20014935L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
NO20014935A 1999-04-14 2001-10-10 Middel for forbedring av ketose NO20014935L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP10711999 1999-04-14
PCT/JP2000/002413 WO2000061127A2 (en) 1999-04-14 2000-04-13 Use of insulin sensitisers for improving ketosis

Publications (2)

Publication Number Publication Date
NO20014935D0 NO20014935D0 (no) 2001-10-10
NO20014935L true NO20014935L (no) 2001-12-12

Family

ID=14450976

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014935A NO20014935L (no) 1999-04-14 2001-10-10 Middel for forbedring av ketose

Country Status (14)

Country Link
US (2) US6677363B1 (zh)
EP (1) EP1169037B1 (zh)
KR (1) KR100697582B1 (zh)
CN (1) CN1222289C (zh)
AT (1) ATE363280T1 (zh)
AU (1) AU3677900A (zh)
CA (1) CA2369694C (zh)
DE (1) DE60035032T2 (zh)
ES (1) ES2283291T3 (zh)
HU (1) HUP0201653A3 (zh)
NO (1) NO20014935L (zh)
PL (1) PL352021A1 (zh)
TW (1) TWI249401B (zh)
WO (1) WO2000061127A2 (zh)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
PL356745A1 (en) * 1999-11-10 2004-06-28 Takeda Chemical Industries, Ltd Body weight gain inhibitors
AU2001232244A1 (en) * 2000-02-10 2001-08-20 Takeda Chemical Industries Ltd. Drug comprising combination
GB0027783D0 (en) * 2000-11-14 2000-12-27 S P A Novel use
WO2002051441A1 (fr) * 2000-12-26 2002-07-04 Sankyo Company, Limited Compositions medicinales contenant un diuretique et un agent renforçant la resistance a l'insuline
DE60233655D1 (de) 2001-04-04 2009-10-22 Ortho Mcneil Janssen Pharm R und retinoid x rezeptorenmodulatoren
CA2442917C (en) 2001-04-04 2011-02-01 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
US20040077689A1 (en) * 2001-04-25 2004-04-22 Yasuo Sugiyama Abc expression promoters
EP1790353A1 (en) * 2001-12-29 2007-05-30 Novo Nordisk A/S Combined use of a GLP-1 compound and a modulator of diabetic late complications
EP1688148A1 (en) * 2002-12-03 2006-08-09 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones
WO2004050115A2 (en) * 2002-12-03 2004-06-17 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones
US7435741B2 (en) * 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
CN105050594B (zh) * 2013-03-19 2019-11-12 南佛罗里达大学 用于产生升高和持久的酮症的组合物和方法
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
US10245242B1 (en) 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10245243B1 (en) 2017-12-19 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10596131B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US10596129B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US10596130B2 (en) 2017-12-19 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
EP3500258A1 (en) * 2016-08-17 2019-06-26 Support-Venture GmbH Method of preventing or treating hearing loss
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
WO2019154893A1 (en) * 2018-02-08 2019-08-15 Strekin Ag Oral extended release pharmaceutical compositions for preventing or treating hearing loss
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US10512615B1 (en) 2018-08-27 2019-12-24 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US10980772B2 (en) 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US11241401B2 (en) 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
KR102180524B1 (ko) * 2018-11-16 2020-11-18 순천대학교 산학협력단 반추동물의 산독증 예방용 완충제 조성물
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
EP0783496B9 (en) * 1994-08-10 2003-09-03 Takeda Chemical Industries, Ltd. Thiazolidinedione derivatives, their production and use
TW403748B (en) * 1994-11-02 2000-09-01 Takeda Chemical Industries Ltd An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
JPH09323930A (ja) 1996-04-04 1997-12-16 Takeda Chem Ind Ltd 悪液質の予防・治療剤
KR100666591B1 (ko) 1997-06-18 2007-01-11 스미스클라인비이참피이엘시이 티아졸리딘디온 및 메트포르민을 사용한 당뇨병의 치료
GB9712866D0 (en) 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
KR100388120B1 (ko) * 1998-05-11 2003-06-18 다케다 야쿠힌 고교 가부시키가이샤 저혈당 및 저지질혈 활성을 갖는 옥시이미노알칸산 유도체
AU754740B2 (en) * 1998-06-30 2002-11-21 Takeda Chemical Industries Ltd. Pharmaceutical composition for the treatment of diabetes
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
ATE362468T1 (de) * 2000-07-25 2007-06-15 Merck & Co Inc N-substituierte indole mit anwendung in der behandlung von diabetes

Also Published As

Publication number Publication date
EP1169037A2 (en) 2002-01-09
ATE363280T1 (de) 2007-06-15
WO2000061127A3 (en) 2001-09-07
WO2000061127A2 (en) 2000-10-19
CN1347319A (zh) 2002-05-01
DE60035032T2 (de) 2008-01-24
NO20014935D0 (no) 2001-10-10
HUP0201653A3 (en) 2004-12-28
EP1169037B1 (en) 2007-05-30
PL352021A1 (en) 2003-07-14
US7595333B2 (en) 2009-09-29
CN1222289C (zh) 2005-10-12
US20040106649A1 (en) 2004-06-03
KR100697582B1 (ko) 2007-03-22
US6677363B1 (en) 2004-01-13
DE60035032D1 (de) 2007-07-12
HUP0201653A2 (en) 2002-09-28
KR20010108497A (ko) 2001-12-07
ES2283291T3 (es) 2007-11-01
CA2369694A1 (en) 2000-10-19
AU3677900A (en) 2000-11-14
CA2369694C (en) 2011-01-04
TWI249401B (en) 2006-02-21

Similar Documents

Publication Publication Date Title
NO20014935D0 (no) Middel for forbedring av ketose
MX225920B (es) Dispersion polimerica termoendurecedora.
GB2420811B (en) Radial expansion system
BR0015191B1 (pt) sistema de suporte de pressão.
ITRM20010464A0 (it) Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica.
SV2001000288A (es) 3- aminoquinazolin - 2, 4 - dione agentes antibacteriales
AU2001229457A1 (en) Selective electrochemical reduction of halogenated 4-aminopicolinic acids
DE59300631D1 (de) Biologisch abbaubare, wässrige Dispersionen.
ES1044815Y (es) Mesa de oficina.
AUPR874601A0 (en) Selective targeting of apoptotic cells
ITBO930030A0 (it) Involucro rigido,particolarmente per sigarette.
ZA200106926B (en) Process for the permanent deformation of keratinous substances employing an organic absorbing agent.
AR023895A1 (es) Nuevos derivados de 6-amino-uracilo, su preparacion y su utilizacion
ITTO20011200A0 (it) Procedimento e apparato di ricezione di segnali radio, particolarmente di tipo numerico multi-portante.
BR0000469B1 (pt) sistema portador.
TR200102093T2 (tr) Organ koruyucu çözeltiler
DK1077956T3 (da) 3-substituerede 5-aryl-4-isoxazolcarbonitriler, der har en anti-viral aktivitet
阿瑟 et al. The Hound of the Baskervilles
NO20013530L (no) Organbeskyttende lösninger
BR9901039A (pt) Sistema de montagem de conjuntos fixados através de parafusos
ATE282611T1 (de) Stolonoxide
ITRM990703A0 (it) Sistema di protezione per radiazioni da onde elettromagnetiche, in particolare per telefoni cellulari.
ES1039654Y (es) Pata perfeccionada, para moviliario de oficina.
BR7903031Y1 (pt) amplificador de forÇas.
IT248469Y1 (it) Doppio foro.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application